Weekly NIH Funding Opportunities and Notices

NIH Guide for Grants and Contracts

March 29, 2019

Table of Contents (TOC)

Web Version

Notices

Notice of Availability of Administrative Supplements for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndromE) Project (Administrative Supplement/ Clinical Trial Optional)
(NOT-OD-19-087)
National Institutes of Health
National Center for Advancing Translational Sciences
National Center for Complementary and Integrative Health
National Cancer Institute
National Eye Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Deafness and Other Communication Disorders
National Institute of Environmental Health Sciences
National Institute of General Medical Sciences
National Institute of Neurological Disorders and Stroke
National Institute of Nursing Research
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
NIH Releases Protocol Template for Behavioral and Social Sciences Research Involving Humans (NOT-OD-19-092) National Institutes of Health
Notice of Change to RFA-AG-20-004 Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
(NOT-AG-19-013)
National Institute on Aging
Notice of Change to PAR-17-039 "Comparative Biology of Neurodegeneration (R21)"
(NOT-AG-19-014)
National Institute on Aging
Broad Agency Announcement (BAA): Development of Vaccines for the Treatment of Opioid Use Disorder BAA-DAIT-75N93019R00009
(NOT-AI-19-052)
National Institute of Allergy and Infectious Diseases
Notice of Budget Change in PAR-18-632 NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
(NOT-AI-19-053)
National Institute of Allergy and Infectious Diseases
Notice of NIAMS Participation in PA-19-196 "Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31)
(NOT-AR-19-037)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Notice of Correction to RFA-CA-19-007 "The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trial Required)"
(NOT-CA-19-037)
National Cancer Institute
Notice of Intent to Publish: Funding Opportunity Announcement for Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
(NOT-CA-19-038)
National Cancer Institute
Notice to Extend the Expiration Date of PA-18-260 :Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)"
(NOT-ES-19-010)
National Institute of Environmental Health Sciences
Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Programs to Enhance Research Training (IPERT) R25
(NOT-GM-19-024)
National Institute of General Medical Sciences
Notice of Informational Webinar on PAR-17-340 "NIGMS Collaborative Program Grant for Multidisciplinary Teams (RM1)"
(NOT-GM-19-031)
National Institute of General Medical Sciences
Notice of NICHD's Participation in PAR-19-158 "Bioengineering Research Grants (BRG) (R01 Clinical Trail Not Allowed)"
(NOT-HD-19-009)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Notice of Availability of Administrative Supplements for Short-term Research Career Enhancement in Genomics for Experienced Investigators
(NOT-HG-19-019)
National Human Genome Research Institute
Notice of Intent to Fund a Strong Heart Study Phase VII Exam
(NOT-HL-19-687)
National Heart, Lung, and Blood Institute
Notice of NHLBI Participation in PA-19-033 "Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)"
(NOT-HL-19-688)
National Heart, Lung, and Blood Institute
Notice of NHLBI Participation in PA-19-034 "Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R43/R44 Clinical Trial Not Allowed)"
(NOT-HL-19-689)
National Heart, Lung, and Blood Institute
Request for Information on the Proposal for Updating the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative Plan
(NOT-NS-19-041)
National Institute of Neurological Disorders and Stroke
National Center for Complementary and Integrative Health
National Eye Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Mental Health
Notice Regarding New Applications for PAR-15-303: "Occupational Safety and Health Education and Research Centers (T42)"
(NOT-OH-19-001)
National Institute for Occupational Safety and Health
Notice Regarding New Applications for PAR-15-352: "Occupational Safety and Health Training Project Grants (T03)"
(NOT-OH-19-002)
National Institute for Occupational Safety and Health
Request for Information (RFI): Identification of Potentially High Value Biomarkers for Predicting Acute to Chronic Pain Transition and Resilience.
(NOT-RM-19-005)
Office of Strategic Coordination (Common Fund)

Requests for Applications

Development of Sample Sparing Assays for Monitoring Immune Responses (U24 Clinical Trial Not Allowed)
(RFA-AI-19-017)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): July 30, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Advancing Biomarker Discovery and Novel Point-of-Care Diagnostics for Active TB Disease Detection in HIV-1 Infected and Exposed Children (R01 Clinical Trial Optional)
(RFA-AI-19-036)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): July 30, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required)
(RFA-CA-19-035)
National Cancer Institute
Application Receipt Date(s): June 28, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
ITCR: innovative algorithms (R21 Clinical Trial Optional)
(RFA-CA-19-038)
National Cancer Institute
Application Receipt Date(s): June 11, 2019; November 20, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
(RFA-CA-19-039)
National Cancer Institute
Application Receipt Date(s): June 11, 2019; November 20, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
(RFA-CA-19-040)
National Cancer Institute
Application Receipt Date(s): June 11, 2019; November 20, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
(RFA-CA-19-041)
National Cancer Institute
Application Receipt Date(s): June 11, 2019; November 20, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Limited Competition: Follow-up on Subjects, Integrative Data Analysis and Measurement of Viral Antibodies in The Environmental Determinants of Diabetes in The Young Study (TEDDY) (U01 Clinical Trial Not Allowed)
(RFA-DK-18-512)
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): June 03, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement.
Renewal Application: Increasing the Quality and Efficiency of Clinical Trials (U18) Clinical Trial Required
(RFA-FD-19-015)
Food and Drug Administration
Application Receipt Date(s): June 3, 2019, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
Cooperative Agreement to Support the World Trade Organization's (WTO) Standards and Trade Development Facility (STDF) (U01 Clinical Trial Not Allowed)
(RFA-FD-19-019)
Food and Drug Administration
Application Receipt Date(s): May 28, 2019 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
Limited Competition Centers of Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEER) (RM1 Clinical Trial Optional)
(RFA-HG-19-012)
National Human Genome Research Institute
Application Receipt Date(s): July 23, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
(RFA-RM-19-007)
Office of Strategic Coordination (Common Fund)
Application Receipt Date(s): September 20, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)
(RFA-RM-19-008)
Office of Strategic Coordination (Common Fund)
Application Receipt Date(s): September 13, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Program Announcements

Pragmatic clinical trial on efficacy of managing reduced iron stores on risk of clinically important events in older adults with heart failure and anemia (U01 Clinical Trial Required)
(PA-19-230)
National Institute on Aging
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)
(PAR-19-231)
National Eye Institute
Application Receipt/Submission Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.